Eran Broshy sold $1.1M of TBPH
director at Theravance Biopharma, Inc.. 59,000 shares at an average of $18.11, traded Nov 11, 2025, filed Nov 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 65% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001256230-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -29,500 | $18.50 | $546k | 61,704 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -15,500 | $17.00 | $264k | 46,204 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -14,000 | $18.50 | $259k | 46,204 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Share Option (Right to Buy)derivative | +14,000 | $10.15 | $142k | 107,878 | Nov 13, 2025 |
Related signals
Other insiders at Theravance Biopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $227k 13,314 shares | -6% | |
| 27Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $583k 31,067 shares | -10% | |
| 17Weak | Theravance Biopharma, Inc. | Eran Broshy director | $590k 29,501 shares | -40% | |
| 12Weak | Theravance Biopharma, Inc. | Eran Broshy director | $809k 45,000 shares | -49% | |
| 5Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $114k 10,000 shares | -3% | |
| 8Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $264k 24,000 shares | -7% | |
| 1Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $36k 4,000 shares | -1% | |
| 1Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $36k 4,000 shares | -1% | |
| 21Weak | TBPHsell Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $36k 4,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.